Home › Funds › Adirondack Capital Advisors, LLC › AQST
Adirondack Capital Advisors, LLC position in AQST
AQUESTIVE THERAPEUTICS INC COM · Health Care
Adirondack Capital Advisors, LLC reported holding 12,000 shares of AQST (AQUESTIVE THERAPEUTICS INC COM) in its Q3 2026 13F filing — a position valued at US$56K, representing 0.03% of its reported portfolio and ranking #44 among its reported holdings. Adirondack Capital Advisors, LLC has disclosed AQST holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR
How Adirondack Capital Advisors, LLC's AQST position evolved
Adirondack Capital Advisors, LLC first disclosed a stake in AQST in Q1 2026 at 12,000 shares (US$50K). The position peaked in Q3 2026 at 12,000 shares, worth US$56K. Across 3 filings, Adirondack Capital Advisors, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 12,000 shares valued at US$56K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 12.00K | $49.80K | New |
| Q2 2026 | 12.00K | $49.92K | Hold |
| Q3 2026 | 12.00K | $55.56K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AQST and 13F data
AQST (AQUESTIVE THERAPEUTICS INC COM) is a Health Care company. 41 other funds we track also report a position in AQST — the largest reported positions include Bratton Capital Management, L.P. (US$40.8M), Samsara BioCapital, LLC (US$10.4M), Sio Capital Management, LLC (US$6.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AQST
- Bratton Capital Management, L.P. 9.81M sh · $40.81M · Q2 2026
- Samsara BioCapital, LLC 2.50M sh · $10.40M · Q2 2026
- Sio Capital Management, LLC 1.49M sh · $6.18M · Q2 2026
- Propel Bio Management, LLC 1.44M sh · $6.00M · Q2 2026
- Blue Owl Capital Holdings LP 942.93K sh · $3.92M · Q2 2026
- DAFNA Capital Management LLC 645.91K sh · $2.69M · Q2 2026
- Everstar Asset Management, LLC 611.94K sh · $2.55M · Q2 2026
- Bracebridge Capital, LLC 459.22K sh · $1.91M · Q2 2026
More on Adirondack Capital Advisors, LLC
FAQ
How long has Adirondack Capital Advisors, LLC held AQST?
Adirondack Capital Advisors, LLC has disclosed AQST holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Adirondack Capital Advisors, LLC's current position in AQST?
As of Q3 2026, Adirondack Capital Advisors, LLC holds 12.00K shares of AQST (AQUESTIVE THERAPEUTICS INC COM), valued at $55.56K, representing 0.03% of its reported portfolio and ranking #44.
Has Adirondack Capital Advisors, LLC been buying or selling AQST?
In the latest 13F filing (Q3 2026), Adirondack Capital Advisors, LLC held unchanged its position in AQST. The position peaked in Q3 2026 at 12.00K shares.
Which other funds hold AQST?
Other major institutional holders of AQST include Bratton Capital Management, L.P., Samsara BioCapital, LLC, Sio Capital Management, LLC, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.